Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy.
Tzu-Fei WangLisa Baumann KreuzigerAvi LeaderGalia SpectreMing Y LimAndrew GahaganRadhika GangarajuKristen M SanfilippoRanjeeta MallickJeffrey I ZwickerMarc CarrierPublished in: Journal of thrombosis and haemostasis : JTH (2021)
In this cohort receiving concurrent DOACs and targeted anticancer therapies, the incidence of bleeding is higher compared to thrombosis, particularly with BTK inhibitors. Future larger prospective studies are needed.
Keyphrases
- direct oral anticoagulants
- venous thromboembolism
- atrial fibrillation
- end stage renal disease
- ejection fraction
- cancer therapy
- newly diagnosed
- chronic kidney disease
- locally advanced
- prognostic factors
- peritoneal dialysis
- type diabetes
- pulmonary embolism
- tyrosine kinase
- adipose tissue
- current status
- skeletal muscle